search
Back to results

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Primary Purpose

Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Empagliflozin 10 MG
Placebo Oral Tablet
Sponsored by
Ann & Robert H Lurie Children's Hospital of Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Alcoholic Fatty Liver Disease

Eligibility Criteria

12 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

For clinical referral to screening visit:

  1. Age: 12 to <20 years old
  2. Diagnosis of Obesity: BMI-percentile ≥95th (using age- and sex- based Center for Disease Control definitions) or BMI ≥30 kg/m2
  3. Elevated alanine aminotransferase (ALT) more than twice the upper limit of normal by gender (≥44 U/L for girls, ≥50 U/L for boys) within 3 months prior to screening (used for historic ALT value) OR diagnosis of NAFLD from ultrasound, MRI, or participants with biopsy-proven NASH within 12 moths of screening
  4. History of lifestyle modification to treat obesity or NAFLD

To be obtained at screening visit:

  1. Confirmation of Obesity
  2. Tanner stage 2
  3. Normal fasting glucose tolerance (fasting blood glucose <100 mg/dL)
  4. If Screening ALT is used as inclusion criteria [if > 2x historic ALT value (historical value obtained clinically within 12 months of screening visit), repeated after 4 weeks [unable to randomize until completed]]. If the repeat ALT is more than 50% increased or decreased over the screening ALT, a third ALT should be obtained. If a third ALT is not within 50% of the previous value, then the subject is ineligible but may be screened at a later date. If ALT is not used:

    • An ultrasound will be done to diagnose NAFLD if the diagnosis has not previously been made by ultrasound, MRI or biopsy
    • A MRI-derived HFF ≥ 5.5%
  5. Willingness to adhere to lifestyle considerations throughout the study

Exclusion Criteria:

  1. ALT > 250U/L at screening
  2. History of significant alcohol intake or current use
  3. Impaired fasting glucose (>100 mg/dL)
  4. Diabetes (type 1 or 2)
  5. Current or recent (<6 months prior to enrollment) use of weight loss medication(s)
  6. Vitamin E supplementation
  7. Previous bariatric surgery
  8. Use of metformin
  9. Prior use of empagliflozin
  10. Lower limb infection/ulceration within 3 months of screening
  11. Metal or magnetic implants, devices or objects inside of or on the body, which are not MRI compatible
  12. Structural and functional urogenital abnormalities, that predispose for urogenital infections
  13. Recent initiation (<3 months prior to enrollment) of anti-hypertensive or lipid medication(s)
  14. Major psychiatric disorder
  15. Current pregnancy or plans to become pregnant.Females unwilling to be tested for pregnancy. Females will be tested for pregnancy. Females who are sexually active and not protected by an effective method of birth control (e.g. UID or medication or patch)
  16. Tobacco use
  17. Significant liver dysfunction (levels >5 times the upper limit of normal (ULN)):

    ALT (ULN = 50 U/L) AST (ULN = 48 U/L) GGT (ULN = 48 U/L) ALP (ULN = 115 U/L)

  18. Platelets < 150,000 cells/mm3
  19. Total bilirubin 1.3 mg/dL
  20. INR 1.3
  21. Albumin <3.2 g/dL
  22. Gilbert's Syndrome
  23. Any known causes of liver disease (except NAFLD and NASH)
  24. Significant renal dysfunction (estimated glomerular filtration rate [eGFR] < 90 mL/min/1.73 m2),
  25. Diagnosed monogenic obesity
  26. History of cancer
  27. Untreated thyroid disorder
  28. History of decompensation events (ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma)
  29. Current or recent (<6 months prior to enrollment) use of medication(s) associated with weight gain (e.g. atypical anti-psychotics)

Sites / Locations

  • University of MinnesotaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Study intervention

Control arm

Arm Description

Empagliflozin 10 mg will be taken daily

Placebo oral tablet will be taken daily

Outcomes

Primary Outcome Measures

Efficacy as Measured by Change in Hepatic Fat Fraction (HFF)
HFF is measured by MRI via 1H- magnetic resonance spectroscopy (MRS). HFF will be measured with single-voxel 1H-MRS on a 3.0 T Trio whole body MRI scanner, using the software package provided by the vendor. The MR elastography measurement will consist of a phase-contrast 2D GRE scan (TR/TE = 50/25 ms, matrix 256 x 90, GRAPPA R=3, slice thickness 7mm) with motion encoding in the z-direction, and acoustic excitation at 60 Hz. Four axial slices will be acquired, each with a single breath-hold. Manual ROIs covering the liver will be drawn on the stiffness maps (in kPa units) generated by the system software. Fibrosis staging will be determined following previously published guidelines.

Secondary Outcome Measures

Change in Body Measurements: Body mass index (BMI)
Height and weight will be measured using a calibrated, wall-mounted stadiometer and an electronic scale, respectively. Three consecutive height and weight measurements will be obtained and averaged. BMI will be calculated as the weight in kilograms divided by the height in meters, squared.
Change in Body Measurements: Body Fat %
Total percent body fat mass and lean muscle mass will be determined by dual energy x-ray absorptiometry (iDXA, GE Healthcare). Body fat percentage is calculated by body fat mass divided by the sum of fat and lean masses.
Change in Body Measurements: Visceral Fat %
Total body fat mass and visceral fat mass will be determined by dual energy x-ray absorptiometry (iDXA, GE Healthcare). Visceral fat percentage of total body mass is calculated by visceral fat mass divided by the sum of total fat and lean masses. Visceral fat percentage of total fat mass is calculated by visceral fat mass divided by total fat mass.
Change in Biomarkers of NAFLD: Alanine transaminase (ALT)
Fasting (≥12 hours) blood will be collected for the measurement of ALT at Fairview Diagnostics Laboratories, Fairview-University Medical Center, Minneapolis, MN - a Center for Disease Control and Prevention certified laboratory.
Change in Biomarkers of NAFLD: Cytokeratin (CK)-18
Fasting plasma samples will be used to measure CK-18 via Luminex Multiplex platform (Millipore, St. Louis, MO).
Change in Blood Pressure
Blood pressure measurements will be obtained manually on the same arm using the same cuff size and equipment. Standardized procedures will be employed as described in previously published standards. Individual cuff size will be determined by measuring the arm circumference midway between the acromial process and the bony olecranon. Sitting blood pressure and heart rate will be measured after the participant has been resting quietly without legs crossed for 10 minutes. Measurements will be made three consecutive times (3-minute intervals). The final two of three independent measurements will be averaged.
Change in Arterial Stiffness
Carotid- and femoral artery augmentation index and carotid-femoral pulse wave velocity (PWV) will be measured by the SphygmoCor® MM3 system (AtCor Medical, Sydney, Australia). Augmentation index is a measure of the relative magnitude of the reflected (or retrograde) pulse wave early in the cardiac cycle. Higher values of augmentation index represent increased arterial stiffening. PWV will be calculated as distance divided by transit time. Since pulse wave transit time decreases in stiffer arterial segments, higher values of pulse wave velocity represent increased arterial stiffness.
Change in Glycemic Control
After fasting measures are completed, we will perform a 2-hour oral glucose tolerance test with fasting (-15 and 0-min) and serial postprandial (15-, 30-, 45-, 60-, 90-, and 120-minutes) plasma concentrations of glucose (glucose oxidase, YSI INC., Yellow Sprigs, OH) and insulin (ELISA, ALPCO Diagnostics, Windham, NH) measured after administration of a 75g glucose challenge. Samples will be batched and a stored for analysis at the completion of the study. Insulin sensitivity will be estimated by the whole-body insulin sensitivity index (WBISI) using plasma glucose and insulin concentrations.
Change in Proton Density Fat Fraction (PDFF) from MRI
A proton density fat fraction (PDFF) image will be acquired using LiverLab's "qdixon" imaging acquisition (3D gradient echo, TR=9ms, flip angle=4°, TE=1.15, 2.46, 3.69, 4.92, 6.15, 7.38 ms, 2x2x3.5mm resolution, one 17s breath-hold). The MRS measurement of HFF will be used as the primary metric. As a secondary endpoint we will use PDFF which has shown promise as a measure of fibrosis staging compared to liver biopsy in children.

Full Information

First Posted
February 28, 2019
Last Updated
January 10, 2023
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
search

1. Study Identification

Unique Protocol Identification Number
NCT03867487
Brief Title
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
Official Title
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2019 (Actual)
Primary Completion Date
May 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Detailed Description
The overall aim of this pilot study is to evaluate the feasibility and obtain a preliminary estimate of efficacy and safety of the SGLT2 inhibitor, empagliflozin, in adolescents with obesity (BMI-percentile ≥95th) who have MRI-confirmed NAFLD (hepatic fat fraction ≥ 5.5%) and have normal fasting glucose. Participants will take empagliflozin, once daily, in the morning, with or without food, in addition to receiving lifestyle/behavioral counseling throughout the study. The following data will be collected throughout the course of the study: Physical exam with tanner staging, safety and fasting labs, fasting blood draw (biomarkers), urine sample, stool sample, OGTT, CGM sensor placement and removal, MRI scan (MRS-Liver), BMI/anthropometrics, urine pregnancy test for female participants, iDXA scan (body fat and bone density), arterial stiffness and blood pressure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
This is a double blind clinical trial in which the study team and the participants are blinded to whether the subject received placebo or study drug.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study intervention
Arm Type
Experimental
Arm Description
Empagliflozin 10 mg will be taken daily
Arm Title
Control arm
Arm Type
Placebo Comparator
Arm Description
Placebo oral tablet will be taken daily
Intervention Type
Drug
Intervention Name(s)
Empagliflozin 10 MG
Other Intervention Name(s)
Jardiance
Intervention Description
Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
Intervention Type
Drug
Intervention Name(s)
Placebo Oral Tablet
Other Intervention Name(s)
Control group
Intervention Description
Participants will take an identical appearing oral tablet with zero active ingredient.
Primary Outcome Measure Information:
Title
Efficacy as Measured by Change in Hepatic Fat Fraction (HFF)
Description
HFF is measured by MRI via 1H- magnetic resonance spectroscopy (MRS). HFF will be measured with single-voxel 1H-MRS on a 3.0 T Trio whole body MRI scanner, using the software package provided by the vendor. The MR elastography measurement will consist of a phase-contrast 2D GRE scan (TR/TE = 50/25 ms, matrix 256 x 90, GRAPPA R=3, slice thickness 7mm) with motion encoding in the z-direction, and acoustic excitation at 60 Hz. Four axial slices will be acquired, each with a single breath-hold. Manual ROIs covering the liver will be drawn on the stiffness maps (in kPa units) generated by the system software. Fibrosis staging will be determined following previously published guidelines.
Time Frame
Baseline to 26 weeks
Secondary Outcome Measure Information:
Title
Change in Body Measurements: Body mass index (BMI)
Description
Height and weight will be measured using a calibrated, wall-mounted stadiometer and an electronic scale, respectively. Three consecutive height and weight measurements will be obtained and averaged. BMI will be calculated as the weight in kilograms divided by the height in meters, squared.
Time Frame
Baseline to 26 weeks
Title
Change in Body Measurements: Body Fat %
Description
Total percent body fat mass and lean muscle mass will be determined by dual energy x-ray absorptiometry (iDXA, GE Healthcare). Body fat percentage is calculated by body fat mass divided by the sum of fat and lean masses.
Time Frame
Baseline to 26 weeks
Title
Change in Body Measurements: Visceral Fat %
Description
Total body fat mass and visceral fat mass will be determined by dual energy x-ray absorptiometry (iDXA, GE Healthcare). Visceral fat percentage of total body mass is calculated by visceral fat mass divided by the sum of total fat and lean masses. Visceral fat percentage of total fat mass is calculated by visceral fat mass divided by total fat mass.
Time Frame
Baseline to 26 weeks
Title
Change in Biomarkers of NAFLD: Alanine transaminase (ALT)
Description
Fasting (≥12 hours) blood will be collected for the measurement of ALT at Fairview Diagnostics Laboratories, Fairview-University Medical Center, Minneapolis, MN - a Center for Disease Control and Prevention certified laboratory.
Time Frame
Baseline to 26 weeks
Title
Change in Biomarkers of NAFLD: Cytokeratin (CK)-18
Description
Fasting plasma samples will be used to measure CK-18 via Luminex Multiplex platform (Millipore, St. Louis, MO).
Time Frame
Baseline to 26 weeks
Title
Change in Blood Pressure
Description
Blood pressure measurements will be obtained manually on the same arm using the same cuff size and equipment. Standardized procedures will be employed as described in previously published standards. Individual cuff size will be determined by measuring the arm circumference midway between the acromial process and the bony olecranon. Sitting blood pressure and heart rate will be measured after the participant has been resting quietly without legs crossed for 10 minutes. Measurements will be made three consecutive times (3-minute intervals). The final two of three independent measurements will be averaged.
Time Frame
Baseline to 26 weeks
Title
Change in Arterial Stiffness
Description
Carotid- and femoral artery augmentation index and carotid-femoral pulse wave velocity (PWV) will be measured by the SphygmoCor® MM3 system (AtCor Medical, Sydney, Australia). Augmentation index is a measure of the relative magnitude of the reflected (or retrograde) pulse wave early in the cardiac cycle. Higher values of augmentation index represent increased arterial stiffening. PWV will be calculated as distance divided by transit time. Since pulse wave transit time decreases in stiffer arterial segments, higher values of pulse wave velocity represent increased arterial stiffness.
Time Frame
Baseline to 26 weeks
Title
Change in Glycemic Control
Description
After fasting measures are completed, we will perform a 2-hour oral glucose tolerance test with fasting (-15 and 0-min) and serial postprandial (15-, 30-, 45-, 60-, 90-, and 120-minutes) plasma concentrations of glucose (glucose oxidase, YSI INC., Yellow Sprigs, OH) and insulin (ELISA, ALPCO Diagnostics, Windham, NH) measured after administration of a 75g glucose challenge. Samples will be batched and a stored for analysis at the completion of the study. Insulin sensitivity will be estimated by the whole-body insulin sensitivity index (WBISI) using plasma glucose and insulin concentrations.
Time Frame
Baseline to 26 weeks
Title
Change in Proton Density Fat Fraction (PDFF) from MRI
Description
A proton density fat fraction (PDFF) image will be acquired using LiverLab's "qdixon" imaging acquisition (3D gradient echo, TR=9ms, flip angle=4°, TE=1.15, 2.46, 3.69, 4.92, 6.15, 7.38 ms, 2x2x3.5mm resolution, one 17s breath-hold). The MRS measurement of HFF will be used as the primary metric. As a secondary endpoint we will use PDFF which has shown promise as a measure of fibrosis staging compared to liver biopsy in children.
Time Frame
Baseline to 26 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: For clinical referral to screening visit: Age: 12 to <20 years old Diagnosis of Obesity: BMI-percentile ≥95th (using age- and sex- based Center for Disease Control definitions) or BMI ≥30 kg/m2 Elevated alanine aminotransferase (ALT) more than twice the upper limit of normal by gender (≥44 U/L for girls, ≥50 U/L for boys) within 3 months prior to screening (used for historic ALT value) OR diagnosis of NAFLD from ultrasound, MRI, or participants with biopsy-proven NASH within 12 moths of screening History of lifestyle modification to treat obesity or NAFLD To be obtained at screening visit: Confirmation of Obesity Tanner stage 2 Normal fasting glucose tolerance (fasting blood glucose <100 mg/dL) If Screening ALT is used as inclusion criteria [if > 2x historic ALT value (historical value obtained clinically within 12 months of screening visit), repeated after 4 weeks [unable to randomize until completed]]. If the repeat ALT is more than 50% increased or decreased over the screening ALT, a third ALT should be obtained. If a third ALT is not within 50% of the previous value, then the subject is ineligible but may be screened at a later date. If ALT is not used: An ultrasound will be done to diagnose NAFLD if the diagnosis has not previously been made by ultrasound, MRI or biopsy A MRI-derived HFF ≥ 5.5% Willingness to adhere to lifestyle considerations throughout the study Exclusion Criteria: ALT > 250U/L at screening History of significant alcohol intake or current use Impaired fasting glucose (>100 mg/dL) Diabetes (type 1 or 2) Current or recent (<6 months prior to enrollment) use of weight loss medication(s) Vitamin E supplementation Previous bariatric surgery Use of metformin Prior use of empagliflozin Lower limb infection/ulceration within 3 months of screening Metal or magnetic implants, devices or objects inside of or on the body, which are not MRI compatible Structural and functional urogenital abnormalities, that predispose for urogenital infections Recent initiation (<3 months prior to enrollment) of anti-hypertensive or lipid medication(s) Major psychiatric disorder Current pregnancy or plans to become pregnant.Females unwilling to be tested for pregnancy. Females will be tested for pregnancy. Females who are sexually active and not protected by an effective method of birth control (e.g. UID or medication or patch) Tobacco use Significant liver dysfunction (levels >5 times the upper limit of normal (ULN)): ALT (ULN = 50 U/L) AST (ULN = 48 U/L) GGT (ULN = 48 U/L) ALP (ULN = 115 U/L) Platelets < 150,000 cells/mm3 Total bilirubin 1.3 mg/dL INR 1.3 Albumin <3.2 g/dL Gilbert's Syndrome Any known causes of liver disease (except NAFLD and NASH) Significant renal dysfunction (estimated glomerular filtration rate [eGFR] < 90 mL/min/1.73 m2), Diagnosed monogenic obesity History of cancer Untreated thyroid disorder History of decompensation events (ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma) Current or recent (<6 months prior to enrollment) use of medication(s) associated with weight gain (e.g. atypical anti-psychotics)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patti Laqua
Phone
651-704-2080
Email
laqua001@umn.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Kelly McCormick
Phone
612-624-3315
Email
kmmccorm@umn.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Justin Ryder, PhD
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patti Laqua
First Name & Middle Initial & Last Name & Degree
Justin Ryder, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

We'll reach out to this number within 24 hrs